Phase 3 Recruiting Network
This phase III trial compares standard chemotherapy to therapy with liposome-encapsulated daunorubicin-cytarabine (CPX-351) and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia with or without FLT3 mutations. Drugs …
Sponsor: Children's Oncology Group
NCT ID: NCT04293562
Sites in District of Columbia: - MedStar Georgetown University Hospital — Washington D.C., District of Columbia
- Children's National Medical Center — Washington D.C., District of Columbia
Phase 3 Recruiting Academic/Other
A study to evaluate if the randomized addition of venetoclax to a chemotherapy backbone (fludarabine/cytarabine/gemtuzumab ozogamicin \[GO\]) improves survival of children/adolescents/young adults with acute myeloid leukemia (AML) in 1st r…
Sponsor: PedAL BCU, LLC
NCT ID: NCT05183035
Sites in District of Columbia: - Children's National - Main Hospital — Washington D.C., District of Columbia
Phase 2 Recruiting NIH
This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04546399
Sites in District of Columbia: - Children's National Medical Center — Washington D.C., District of Columbia
Phase 1, Phase 2 Recruiting Academic/Other
This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back a…
Sponsor: PedAL BCU, LLC
NCT ID: NCT04726241
Sites in District of Columbia: - MedStar Georgetown University Hospital — Washington D.C., District of Columbia
- Children's National Medical Center — Washington D.C., District of Columbia
Phase 1, Phase 2 Recruiting Academic/Other
This is a phase IB/II study with a 3+3 dose de-escalation study design. Patients will continue maintenance treatment with CPX-351 for 6 cycles on D1 and D3, as long as patient remains in CR. The dose de-escalation will be one dose given on…
Sponsor: Georgetown University
NCT ID: NCT04990102
Sites in District of Columbia: - Georgetown Lombardi Comprehensive Cancer Center — Washington D.C., District of Columbia
Phase 1 Recruiting Academic/Other
A Phase I trial to determine the safety of targeted immunotherapy with daratumumab (DARA) IV after total body irradiation (TBI)-based myeloablative conditioning and allogeneic hematopoietic cell transplantation (HCT) for children, adolesce…
Sponsor: New York Medical College
NCT ID: NCT04972942
Sites in District of Columbia: - Children's National Medical Center — Washington D.C., District of Columbia
Phase 1 Recruiting Academic/Other
This Phase I dose-escalation trial is designed to evaluate the safety of administering rapidly -generated tumor multi-antigen associated -specific cytotoxic T lymphocytes, to HSCT recipients with high risk AML and MDS.
Sponsor: Catherine Bollard
NCT ID: NCT02203903
Sites in District of Columbia: - Childrens National Medical Center — Washington D.C., District of Columbia
Recruiting Network
This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.
Sponsor: Center for International Blood and Marrow Transplant Research
NCT ID: NCT01351545
Sites in District of Columbia: - Children's National Medical Center — Washington D.C., District of Columbia
NA Recruiting Academic/Other
This study aims to determine the impact of massage therapy for pediatric patients receiving intensive chemotherapy or stem cell transplant (SCT).
Sponsor: Children's Hospital of Philadelphia
NCT ID: NCT06892158
Sites in District of Columbia: - Children's National Hospital — Washington D.C., District of Columbia
NA Recruiting Academic/Other
Over 90% of children and adolescents diagnosed with acute lymphoblastic leukemia (ALL) will survive long term. Part of the successful treatment that patients receive is the delivery of chemotherapy directly into their spinal fluid via a sp…
Sponsor: Children's National Research Institute
NCT ID: NCT06722638
Sites in District of Columbia: - Children's National Hospital — Washington D.C., District of Columbia
NA Recruiting Academic/Other
This is a multicenter pilot randomized controlled trial, with an active control condition, of the feasibility, acceptability, and preliminary efficacy of EndeavorRx in a cohort of survivors of acute lymphoblastic leukemia or brain tumor ag…
Sponsor: Children's National Research Institute
NCT ID: NCT05528939
Sites in District of Columbia: - Children's National Hospital — Washington D.C., District of Columbia